Chuan-ben Chen

Fuzhou, China

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications

A Phase 1 study of subcutaneous toripalimab in recurrent or metastatic nasopharyngeal carcinoma.

A Phase 1 study of subcutaneous toripalimab in recurrent or metastatic nasopharyngeal carcinoma.

Journal: British journal of clinical pharmacology
Published: September 08, 2025

Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma: The DIPPER Randomized Clinical Trial.

Adjuvant PD-1 Blockade With Camrelizumab for Nasopharyngeal Carcinoma: The DIPPER Randomized Clinical Trial.

Journal: JAMA
Published: March 13, 2025

DNA-PKcs Dysfunction Enhances the Antitumor Activity of Radioimmunotherapy by Activating the cGAS-STING Pathway in HNSCC.

DNA-PKcs Dysfunction Enhances the Antitumor Activity of Radioimmunotherapy by Activating the cGAS-STING Pathway in HNSCC.

Journal: Journal of inflammation research
Published: September 23, 2024

Establishment and validation of circulating cell-free DNA signatures for nasopharyngeal carcinoma detection.

Establishment and validation of circulating cell-free DNA signatures for nasopharyngeal carcinoma detection.

Journal: EBioMedicine
Published: January 18, 2024

Role of PET/CT in improving the cost effectiveness of nimotuzumab in nasopharyngeal carcinoma.

Role of PET/CT in improving the cost effectiveness of nimotuzumab in nasopharyngeal carcinoma.

Journal: Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale
Published: September 22, 2023

Development and validation of a model based on immunogenic cell death related genes to predict the prognosis and immune response to bladder urothelial carcinoma.

Development and validation of a model based on immunogenic cell death related genes to predict the prognosis and immune response to bladder urothelial carcinoma.

Journal: Frontiers in oncology
Published: September 10, 2023

A senescence-related lncRNA signature predicts prognosis and reflects immune landscape in HNSCC.

A senescence-related lncRNA signature predicts prognosis and reflects immune landscape in HNSCC.

Journal: Oral oncology
Published: July 16, 2023

An Immunogenic Cell Death-Related Gene Signature Reflects Immune Landscape and Predicts Prognosis in Melanoma Independently of BRAF V600E Status.

An Immunogenic Cell Death-Related Gene Signature Reflects Immune Landscape and Predicts Prognosis in Melanoma Independently of BRAF V600E Status.

Journal: BioMed research international
Published: November 20, 2022

Construction and validation of a prognostic model based on stage-associated signature genes of head and neck squamous cell carcinoma: a bioinformatics study.

Construction and validation of a prognostic model based on stage-associated signature genes of head and neck squamous cell carcinoma: a bioinformatics study.

Journal: Annals of translational medicine
Published: October 17, 2022

An EGFR L858R mutation identified in 1862 Chinese NSCLC patients can be a promising neoantigen vaccine therapeutic strategy.

An EGFR L858R mutation identified in 1862 Chinese NSCLC patients can be a promising neoantigen vaccine therapeutic strategy.

Journal: Frontiers in immunology
Published: August 18, 2022

FAM3D as a Prognostic Indicator of Head and Neck Squamous Cell Carcinoma Is Associated with Immune Infiltration.

FAM3D as a Prognostic Indicator of Head and Neck Squamous Cell Carcinoma Is Associated with Immune Infiltration.

Journal: Computational and mathematical methods in medicine
Published: July 11, 2022

The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma.

The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma.

Journal: Cancer communications (London, England)
Published: July 17, 2021
Showing 1-12 of 15

Last Updated: 09/26/2026